Top ▲
target has curated data in GtoImmuPdb
Target id: 3010
Nomenclature: CD37 molecule
Abbreviated Name: CD37
Family: CD molecules, Tetraspanins
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 4 | 281 | 19q13.33 | CD37 | CD37 molecule | 14 |
| Mouse | - | 303 | 7 B3; Ch 7, 29.20 cM | Cd37 | CD37 antigen | |
| Rat | 4 | 281 | 1q22 | Cd37 | CD37 molecule | |
| Gene and Protein Information Comments | ||||||
| The human CD37 gene produces two transcript variants and two protein isoforms: isoform A is 281 aa, isoform B is shorter at its N-terminus and is 213 aa. The longest mouse protein isoform (1) is 303 aa, isoform 2 is 278 aa, and isoform 3 is 281 aa. | ||||||
| Previous and Unofficial Names |
| CD37 antigen | tetraspanin 26 | TSPAN26 |
| Database Links |
|
| Alphafold | P11049 (Hs), P31053 (Rn) |
| ChEMBL Target | CHEMBL3712880 (Hs) |
| Ensembl Gene | ENSG00000104894 (Hs), ENSMUSG00000030798 (Mm), ENSRNOG00000020699 (Rn) |
| Entrez Gene | 951 (Hs), 12493 (Mm), 29185 (Rn) |
| Human Protein Atlas | ENSG00000104894 (Hs) |
| KEGG Gene | hsa:951 (Hs), mmu:12493 (Mm), rno:29185 (Rn) |
| OMIM | 151523 (Hs) |
| Pharos | P11049 (Hs) |
| RefSeq Nucleotide | NM_001774 (Hs), NM_001040031 (Hs), NM_001290802 (Mm), NM_001290804 (Mm), NM_007645 (Mm), NM_017124 (Rn) |
| RefSeq Protein | NP_001035120 (Hs), NP_001765 (Hs), NP_031671 (Mm), NP_001277731 (Mm), NP_001277733 (Mm), NP_058820 (Rn) |
| UniProtKB | P11049 (Hs), P31053 (Rn) |
| Wikipedia | CD37 (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CD37 is included in GtoImmuPdb as it is an immuno-oncology target that is being expoited for the development of novel therapeutics for the treatment of B cell malignancies, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [5,9,12,15]. |
| Cell Type Associations | ||||||||
|
||||||||
|
| Physiological Consequences of Altering Gene Expression
|
||||||||||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
| General Comments |
| The CD37 protein has 4 hydrophobic transmembrane domains, and it belongs to the tetraspanin (TSPAN) protein family (HGNC family ID 768) [2,13]. It is expressed solely by cells of the immune system, and is involved in the regulation of immune responses [7], cell-cell interactions, cell development, activation, growth and motility [2,13]. CD37 is found on normal and malignant B cells. It has been identified as a tumour suppressor that protects against B cell lymphomagenesis, an effect that is mediated by inhibiting the IL-6 pathway [4], and in support of this mechanism is the observation that in human lymphomas CD37 deficiency is a marker of poor prognosis [16]. |
1. Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, Giralt M, Romero M, Perdiguer L, Delgado M, Orfao A et al.. (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia, 19 (8): 1376-83. [PMID:15931266]
2. Charrin S, le Naour F, Silvie O, Milhiet PE, Boucheix C, Rubinstein E. (2009) Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J, 420 (2): 133-54. [PMID:19426143]
3. Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. (2013) Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res, 33 (1): 85-95. [PMID:23267131]
4. de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S et al.. (2016) Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest, 126 (2): 653-66. [PMID:26784544]
5. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J et al.. (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood, 122 (20): 3500-10. [PMID:24002446]
6. Knobeloch KP, Wright MD, Ochsenbein AF, Liesenfeld O, Löhler J, Zinkernagel RM, Horak I, Orinska Z. (2000) Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol, 20 (15): 5363-9. [PMID:10891477]
7. Levy S, Shoham T. (2005) The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol, 5 (2): 136-48. [PMID:15688041]
8. Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA, Levy R. (1986) A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol, 137 (9): 3013-8. [PMID:3489782]
9. Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. (2015) Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol, 168 (1): 38-45. [PMID:25146490]
10. Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R et al.. (2013) Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. MAbs, 5 (5): 723-35. [PMID:23883821]
11. Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G. (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol, 140 (3): 905-14. [PMID:3257508]
12. Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. (2018) Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs, 36 (5): 869-876. [PMID:29453628]
13. van Deventer SJ, Dunlock VE, van Spriel AB. (2017) Molecular interactions shaping the tetraspanin web. Biochem Soc Trans, 45 (3): 741-750. [PMID:28620035]
14. Virtaneva KI, Angelisová P, Baumruker T, Horejsí V, Nevanlinna H, Schröder J. (1993) The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes. Immunogenetics, 37 (6): 461-5. [PMID:8436422]
15. Witkowska M, Smolewski P, Robak T. (2018) Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. Expert Opin Investig Drugs, 27 (2): 171-177. [PMID:29323537]
16. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J et al.. (2016) Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 128 (26): 3083-3100. [PMID:27760757]
CD molecules: CD37 molecule. Last modified on 05/11/2020. Accessed on 16/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3010.
